For infants with extreme immaturity and infants with congenital heart disease and congestive heart failure who meet the criteria established by the American Academy of Pediatrics.
- Synagis
For infants who are less than 8 months and older children who have underlying risks.
- Beyfortus (Nirsevimab)
Injections for patients with severe persistent asthma who meet the criteria established by the FDA.
- Xolair
- Fasenra
- Nucala
- Tezspire
- Others as approved by the FDA
